BOSTON, March 17, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today announced that it has
been named for the second consecutive year to the FlexJobs Top 100
Companies to Watch for Remote Jobs in 2015. The list
recognizes companies with flexible job opportunities and is
intended to guide job seekers in their search for companies with a
successful track record of recruiting and hiring telecommuters.
PAREXEL offers nearly 20 percent of its global employees
flexible work options, including telecommuting, flexible schedules,
and home-based employment. In North America, more than 40
percent of PAREXEL's employees take advantage of flexible
employment opportunities. These employees represent a diverse cross
section of positions, including clinical research, biostatistics,
and regulatory affairs.
"We understand that in today's fast-paced, globally connected
world, employment flexibility can lead to a more engaged, more
satisfied workforce – both key to PAREXEL providing the highest
level of client satisfaction," said Tom
McGoldrick, Vice President of Talent Acquisition, PAREXEL.
"PAREXEL's varied work options also provide access to a skilled
labor force without geographic restrictions, which is essential for
meeting organizational growth and helping our clients simplify
their journey towards bringing new treatments to the patients who
need them around the world."
About the Ranking
FlexJobs, a job service specializing
in remote and flexible job opportunities, analyzed its database of
over 30,000 companies' job posting history from the prior year to
determine which companies would be most likely to incorporate
telecommuting into their 2015 hiring practices. In 2015, PAREXEL
ranked 17th in the top 100.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of expertise-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston, Massachusetts, PAREXEL operates in 81
locations in 51 countries around the world, and has approximately
16,530 employees. For more information about PAREXEL
International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition of ClinIntel Limited, or enter into new
lines of business; the impact on the Company's business of
government regulation of the drug, medical device and
biotechnology industry; consolidation within the pharmaceutical
industry and competition within the biopharmaceutical services
industry; the potential for significant liability to clients and
third parties; the potential adverse impact of health care reform;
and the effects of foreign currency exchange rate fluctuations and
other international economic, political, and other
risks. Such factors and others are discussed more fully
in the section entitled "Risk Factors" of the Company's Quarterly
Report on Form 10-Q for the quarter ended December 31,
2014 as filed with the Securities and Exchange Commission
on February 5, 2015, which "Risk Factors" discussion is
incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL
International
Tel: +1
781-434-5516
Email:
Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-named-a-2015-flexjobs-top-100-company-for-remote-jobs-300050857.html
SOURCE PAREXEL International Corporation